BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//American Academy of Pediatrics - ECPv6.8.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://aapca2.org
X-WR-CALDESC:Events for American Academy of Pediatrics
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20231116T121500
DTEND;TZID=America/Los_Angeles:20231116T130000
DTSTAMP:20260621T033003
CREATED:20231030T173359Z
LAST-MODIFIED:20231030T174112Z
UID:10730-1700136900-1700139600@aapca2.org
SUMMARY:TZIELD Potential To Delay Stage 3 T1D
DESCRIPTION:Provention Bio invites you to attend a Webcast program titled TZIELDTM: Potential to Delay Stage 3 T1D. This event will take place on November 16th @ 12:15PM! TZIELD™ (teplizumab-mzwv) is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. This webinar will inform attendees all about it. Learn more below! \nDownload Flier \nClick To RSVP
URL:https://aapca2.org/event/tzield-potential-to-delay-stage-3-t1d/
LOCATION:Zoom
END:VEVENT
END:VCALENDAR